Correspondence 0001213900-23-059663 from ADIAL PHARMACEUTICALS, INC. (ADIL)
ADIAL PHARMACEUTICALS, INC.
Date: July 25, 2023 · CIK: 0001513525 · Accession: 0001213900-23-059663
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-272846
Letter
VIA EDGAR United States Securities Division of Corporation Finance Registration Statement on Form S-1 (as amended) Filed June 23, 2023 File No: 333-272846
Re: Adial Pharmaceuticals, Inc.
Dear Sir or Madam:
Adial Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1, as amended (File No. 333-272846), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to become effective on Thursday, July 27, 2023, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Leslie Marlow and/or Hank Gracin of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238, or Mr. Gracin at (561) 926-7995 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
Very truly yours,
ADIAL PHARMACEUITCALS, INC.
Show Raw Text
CORRESP
1
filename1.htm
July 25, 2023
VIA EDGAR
United States Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Adial Pharmaceuticals, Inc.
Registration Statement on Form S-1 (as amended)
Filed June 23, 2023
File No: 333-272846
Dear Sir or Madam:
Adial Pharmaceuticals, Inc.
(the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1,
as amended (File No. 333-272846), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”)
to become effective on Thursday, July 27, 2023, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands
that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities
under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes
Leslie Marlow and/or Hank Gracin of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow
at (516) 457-4238, or Mr. Gracin at (561) 926-7995 with any questions you may have concerning this request, and please notify either of
them when this request for acceleration has been granted.
Very truly yours,
ADIAL PHARMACEUITCALS, INC.
By:
/s/ Cary Claiborne
Name:
Cary Claiborne
Title:
Chief Executive Officer
cc: Leslie Marlow, Blank Rome LLP
Hank Gracin, Blank Rome LLP